Month: October 2025

Ashvattha Therapeutics Appoints Ophthalmology Veteran Robert J. Dempsey as Interim CEO Following Positive Phase 2 Results and FDA Alignment on Pivotal Program

by

FDA agrees with Phase 2b/3 clinical design, including primary endpoint and development approach, providing clear regulatory pathway to conduct two studies under single protocol Dempsey brings proven track record of ophthalmology commercialization and will present company update at Eyecelerator ahead of American Academy of Ophthalmology Annual Meeting 2025   REDWOOD CITY, Calif., October 14, 2025 … Read more

Ashvattha Therapeutics to Present Phase 2 DME and nAMD Data at Innovate Retina

by

Migaldendranib (MGB), a subcutaneous nanomedicine, represents potential paradigm shift from frequent intravitreal injections   REDWOOD CITY, Calif., October 8, 2025 — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood-retinal barrier in regions of inflammation selectively targeting and reprogramming activated cells in the retina, today announced an upcoming presentation at … Read more